Comparing Alzheimer's blood markers across ethnic groups in Barcelona
Studies whether Alzheimer's blood marker levels differ between ethnic groups in Barcelona.
Plain-language title generated from the registry record
Registry title: DIV-AD BARCELONA: Alzheimer's Blood-Based Biomakers for a Diverse Community
Key facts
- Where
- Barcelona, SpainSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 75 years old?
Source: NCT07521722, who can take part
Where in Spain
- BarcelonaBeta Brain Research Center - EAP Raval SudBarcelona, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
- Trial code
- NCT07521722
- Record updated
- 13 April 2026
- Original description
The DIV-AD study aims to find out whether levels of Alzheimer's disease markers in blood differ among the main ethnical groups living in central Barcelona.Read full original descriptionShow less
DIV-AD BARCELONA: Alzheimer's Blood-Based Biomakers for a Diverse Community
The DIV-AD study aims to find out whether levels of Alzheimer's disease markers in blood differ among the main ethnical groups living in central Barcelona.
It will also examine how factors such as age, income, education, and health conditions may affect these levels.
In addition, the study will identify barriers that may make it difficult to use these blood tests in primary care.
The final goal is to help ensure that everyone in Barcelona has fair access to early prevention strategies for Alzheimer's disease.
Inclusion: Cognitively Unimpaired individuals aged between 50 and 75 years at the time of signing the informed consent; Individuals interested in participating, able to follow study procedures, and who understand that all the tests are carried out in a research context; Explicit desire to participate in the tests and procedures of the study, including: collection of study variables, cognitive and neurologic assessment, blood sampling; Signing the informed consent, agreeing not to receive the research results that will not be of no clinical interest for the participant.
Exclusion: Individuals with cognitive complaints and who have sought for medical help for cognitive impairment at any time in their life; Patients with relevant medical illnesses that may significantly interfere with the interpretation of results. This includes auditory and visual perception disorders, active oncological disease under treatment (localized tumors are excluded) and any condition that, in the investigator's opinion, may interfere with the correct performance/interpretation of the study procedures and/or with future permanence in the study; Major psychiatric disorders (according to the DSM-V manual) or diseases that affect cognitive abilities (major depressive episode, bipolar disorder, schizophrenia, etc); Acquired brain damage: history of head trauma with macroscopic parenchymal or non-axial lesion, large-vessel ischemic or hemorrhagic stroke, brain tumours and any other etiologies that can cause acquired brain damage (i.e., chemotherapy or brain radiotherapy); Parkinson's disease, epilepsy under treatment and with frequent seizures (> 1/month) in the last year, multiple sclerosis or other neurodegenerative diseases; Cognitive decline defined by CDR>0.